Inova ends genetic tests following FDA warning

Falls Church, Va.-based Inova Health System announced that it will cease using its five proprietary MediMap genetic tests after the FDA issued a warning about their unauthorized usage, according to the Washington Business Journal.

The nonprofit health organization's MediMap tests were used by physicians in the Inova Genomics Laboratory to predict drug dosage, side effects and efficiency for patients.

On April 4, the FDA issued a letter to Inova warning that claims on the lab's website were in violation of the Federal Food, Drug, and Cosmetic Act. Though Inova claimed the MediMap tests could predict patient responses to drugs, the FDA noted that it had not approved the tests' safety and accuracy.

More articles on health IT:
Harvard Medical School's AI screening system could produce more accurate cancer treatment programs
Microsoft emails users about data breach within customer support platform
California nursing program uses human-like robots to train medical personnel  

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months